Opportunity Information: Apply for PA 14 025
Apply for PA 14 025
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Discovering Novel Targets The Molecular Genetics of Drug Addiction and Related Co Morbidities (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 10, 2013 and posted on Dec 10, 2013.
- Applicants must submit their applications by Jan 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments City or township governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses For profit organizations other than small businesses Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Private institutions of higher education Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PA-14-025, titled "Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)," supports research projects aimed at finding and confirming genetic factors that shape a persons risk for developing drug addiction and that help predict how well someone may respond to treatment. The core idea is to move beyond broad descriptions of addiction and pinpoint specific chromosomal regions (loci) and gene variants that contribute to addiction vulnerability, addiction-related traits, and co-occurring conditions. By emphasizing target discovery and validation, the announcement is geared toward work that can sharpen the biological understanding of addiction and potentially guide future prevention and treatment strategies, including more personalized approaches.
A major scientific emphasis in the announcement is the use of intermediate phenotypes, often called endophenotypes, to bridge the gap between genes and complex clinical outcomes. Rather than relying only on a diagnosis of substance use disorder, applicants are encouraged to study measurable traits that are more directly tied to underlying biology, such as drug sensitivity, craving, stress reactivity, impulsivity, reward processing, tolerance, withdrawal severity, or cognitive and emotional traits that commonly travel with addiction. The FOA also highlights co-morbidities, recognizing that addiction frequently overlaps with other psychiatric, behavioral, and medical conditions, and that shared genetic architecture may help explain why these conditions cluster together. Projects that clarify how endophenotypes and co-morbid traits relate to addiction risk and course are seen as especially responsive.
Methodologically, the announcement invites a wide range of human genetics and genomics approaches, along with computational and large-scale analytic strategies. Examples explicitly encouraged include linkage studies, linkage disequilibrium analyses, case-control designs, and family-based studies, as well as integrative approaches that combine multiple datasets or connect study findings with external databases. In practical terms, that could involve leveraging genome-wide association data, sequencing, imputation, polygenic risk modeling, pathway and network analyses, or meta-analytic and harmonization strategies that increase statistical power. The FOA makes it clear that projects can incorporate data integration as a central component, particularly when external resources can enrich substance use genetics and genomics research.
The FOA is flexible about where data come from. Studies may collect primary data or analyze existing datasets (secondary data analysis is explicitly allowed). Data sources can include general population samples, special populations (for example, groups defined by clinical features, exposure history, or other characteristics), recently admixed populations (which can be informative for genetic mapping but require careful analytic handling), and non-human animal models. By allowing animal models alongside human studies, the announcement supports translational designs where genetic signals can be tested in controlled systems, or where mechanistic work in animals can inform interpretation of human genetic findings.
Another key encouragement is to treat addiction genetics as more than a single-gene or single-environment story. Applicants are urged, when appropriate, to incorporate gene by gene interactions, gene by environment interactions, and even gene by environment by development interactions. This reflects the reality that genetic risk may express differently depending on environmental exposures (such as trauma, stress, peer context, socioeconomic conditions, early substance exposure, or availability of drugs) and developmental stage (childhood, adolescence, adulthood). Pharmacogenetics is also highlighted, aligning with the FOAs interest in genetic predictors of treatment response and the possibility of matching interventions to biological profiles. Inclusion of non-human models is encouraged when useful for validation, functional follow-up, or probing causal pathways.
Administratively, this opportunity uses the NIH R01 mechanism, which is designed for mature, hypothesis-driven or discovery-oriented research projects of substantial scope. The funding instrument type is a grant, and the activity category is health. It is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs). The agency is the National Institutes of Health. The announcement states that there is no cost sharing or matching requirement, which generally means applicants are not required to contribute non-federal funds as a condition of the award.
Eligibility is broad and includes many organization types across the public, nonprofit, academic, and private sectors. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), small businesses, and for-profit organizations (including those other than small businesses). Government applicants may include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. Tribal eligibility includes federally recognized Native American tribal governments and tribal organizations that are not federally recognized. The FOA also explicitly includes a range of mission-driven institutions and community-based entities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions. Foreign participation is permitted: non-U.S. organizations and foreign institutions may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy.
In terms of timing, the opportunity was posted and created on December 10, 2013, with an original and current closing date of January 7, 2017, and an archive date of February 7, 2017, meaning the specific FOA is no longer active but remains available for reference. The full announcement was hosted through the NIH Grants Guide under PA-14-025, and NIH provided a contact route through the NIH Office of Extramural Research web support for access or linking problems.
Overall, the FOA is best understood as a call for rigorous, genetics-focused addiction research that can identify actionable biological targets, clarify mechanisms through endophenotypes and co-morbid traits, and improve the ability to predict vulnerability and treatment response. It favors projects that combine strong study designs with modern genomic and computational tools, that thoughtfully account for interaction effects and developmental context, and that make strategic use of existing datasets, diverse populations, and translational models to strengthen discovery and validation.
Frequently Asked Questions (FAQs)
What is the NIH funding opportunity PA-14-025?
PA-14-025 is an NIH Funding Opportunity Announcement (FOA) titled "Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)." It supports research aimed at identifying and validating genetic factors that influence risk for drug addiction and related co-morbidities, and that may help predict treatment response.
What is the main goal of this FOA?
The core goal is to move beyond broad descriptions of addiction and pinpoint specific chromosomal regions (loci) and gene variants that contribute to addiction vulnerability, addiction-related traits, and co-occurring conditions, with an emphasis on target discovery and validation.
What kind of research does this opportunity emphasize?
The FOA emphasizes rigorous genetics and genomics research focused on discovering and confirming genetic contributors to addiction and related traits, improving biological understanding, and supporting future prevention and treatment strategies, including more personalized approaches.
What are "endophenotypes" and why are they important in this FOA?
Endophenotypes (also called intermediate phenotypes) are measurable traits that help bridge the gap between genes and complex clinical outcomes. The FOA highlights them because they can be more directly tied to underlying biology than a diagnosis alone and can clarify pathways from genetic variation to addiction risk and course.
What are examples of endophenotypes mentioned in the announcement?
Examples include drug sensitivity, craving, stress reactivity, impulsivity, reward processing, tolerance, withdrawal severity, and cognitive or emotional traits that commonly co-occur with addiction.
Does the FOA focus only on addiction diagnoses (substance use disorder)?
No. While addiction outcomes are relevant, applicants are encouraged to study measurable intermediate traits (endophenotypes) rather than relying only on diagnostic categories.
How does the FOA address co-morbidities?
The FOA highlights that addiction frequently overlaps with other psychiatric, behavioral, and medical conditions. It encourages projects that examine shared genetic architecture and clarify how co-morbid traits and endophenotypes relate to addiction risk and trajectory.
What study designs and methods are encouraged?
The FOA invites a wide range of human genetics and genomics approaches and large-scale analytic strategies, including linkage studies, linkage disequilibrium analyses, case-control designs, and family-based studies.
Does the FOA encourage computational and integrative analyses?
Yes. Integrative approaches that combine multiple datasets or connect findings with external databases are explicitly encouraged, particularly when they can strengthen substance use genetics and genomics research.
What kinds of genomic and analytic approaches are mentioned as examples?
Examples include leveraging genome-wide association data, sequencing, imputation, polygenic risk modeling, pathway and network analyses, meta-analysis, and harmonization strategies that increase statistical power.
Can applicants use existing data instead of collecting new data?
Yes. Secondary data analysis is explicitly allowed, and projects may either collect primary data or analyze existing datasets.
What types of populations or samples can be used?
Data sources can include general population samples, special populations (such as groups defined by clinical features or exposure history), and recently admixed populations. The FOA notes that admixed populations can be informative for mapping but require careful analytic handling.
Are non-human animal models allowed under this FOA?
Yes. The FOA allows non-human animal models alongside human studies, supporting translational designs, validation in controlled systems, and mechanistic work that informs interpretation of human genetic findings.
Does the FOA encourage gene-by-environment or interaction analyses?
Yes. Applicants are urged, when appropriate, to incorporate gene-by-gene interactions, gene-by-environment interactions, and gene-by-environment-by-development interactions to reflect how genetic risk can vary by exposure and life stage.
What kinds of environmental factors are referenced as relevant?
Examples mentioned include trauma, stress, peer context, socioeconomic conditions, early substance exposure, and drug availability.
Does the FOA include a developmental perspective?
Yes. It notes that genetic risk may express differently across developmental stages, including childhood, adolescence, and adulthood, and encourages consideration of development where appropriate.
Is pharmacogenetics included in the scope of this opportunity?
Yes. Pharmacogenetics is highlighted in alignment with the FOA's interest in genetic predictors of treatment response and the possibility of matching interventions to biological profiles.
What grant mechanism does this FOA use?
This opportunity uses the NIH R01 mechanism, which is intended for mature, hypothesis-driven or discovery-oriented research projects of substantial scope.
What is the funding instrument type and activity category?
The funding instrument is a grant, and the activity category is health.
What is the CFDA number associated with this opportunity?
The FOA is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Which agency sponsors this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement, meaning applicants are generally not required to contribute non-federal funds as a condition of the award.
Who is eligible to apply?
Eligibility is broad and includes public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), small businesses, and for-profit organizations (including those other than small businesses).
Are government entities eligible applicants?
Yes. Eligible government applicants include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are tribal entities eligible to apply?
Yes. The FOA includes federally recognized Native American tribal governments and also tribal organizations that are not federally recognized.
Does the FOA specifically include mission-driven and community-based institutions?
Yes. The FOA explicitly includes institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions.
Is foreign participation allowed?
Yes. Non-U.S. organizations and foreign institutions may apply, non-U.S. components of U.S. organizations are eligible, and foreign components are allowed as defined by NIH policy.
Is PA-14-025 still open?
No. The FOA was posted/created on December 10, 2013. The closing date listed is January 7, 2017, and the archive date is February 7, 2017, indicating the specific FOA is no longer active and remains available for reference.
Where was the full announcement hosted?
The full announcement was hosted through the NIH Grants Guide under PA-14-025.
What if someone has technical issues accessing the announcement?
The NIH provided a contact route through the NIH Office of Extramural Research web support for access or linking problems.
What kinds of projects are described as especially responsive to this FOA?
Projects that clarify how endophenotypes and co-morbid traits relate to addiction risk and course are described as especially responsive, particularly when they strengthen target discovery and validation and make strategic use of strong designs and modern genomic and computational tools.
Browse more opportunities from the same category: Education Health
Next opportunity: Computational Analyses Exploiting Reference Epigenomic Maps (R01)
Previous opportunity: NIH/PEPFAR Collaboration for Implementation Science (Admin Supp)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 14 025
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 14 025) also looked into and applied for these:
| Funding Opportunity |
|---|
| Basic Mechanisms of Brain Development for Substance Use and Dependence (R01) Apply for PA 14 026 Funding Number: PA 14 026 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2013 and 2014 (P50) Apply for PAR 14 031 Funding Number: PAR 14 031 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Chronic Illness Self Management in Children and Adolescents (R01) Apply for PA 14 029 Funding Number: PA 14 029 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Chronic Illness Self Management in Children and Adolescents (R21) Apply for PA 14 030 Funding Number: PA 14 030 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Reducing Health Disparities Among Minority and Underserved Children (R21) Apply for PA 14 034 Funding Number: PA 14 034 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Reducing Health Disparities Among Minority and Underserved Children (R01) Apply for PA 14 033 Funding Number: PA 14 033 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Women Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R21) Apply for PA 14 036 Funding Number: PA 14 036 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Women Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03) Apply for PA 14 037 Funding Number: PA 14 037 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Women Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R01) Apply for PA 14 038 Funding Number: PA 14 038 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Early Stage Innovative Molecular Analysis Technology Development for Cancer Research (R21) Apply for RFA CA 14 003 Funding Number: RFA CA 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Early Stage Development of Innovative Technologies for Biospecimen Science (R21) Apply for RFA CA 14 005 Funding Number: RFA CA 14 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Biospecimen Science (R33) Apply for RFA CA 14 006 Funding Number: RFA CA 14 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Validation and Advanced Development of Emerging Molecular Analysis Technologies for Cancer Research (R33) Apply for RFA CA 14 004 Funding Number: RFA CA 14 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Using Social Media to Understand and Address Substance Use and Addiction (R01) Apply for RFA CA 14 008 Funding Number: RFA CA 14 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Using Social Media to Understand and Address Substance Use and Addiction (R21) Apply for RFA CA 14 009 Funding Number: RFA CA 14 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PA 14 061 Funding Number: PA 14 061 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21) Apply for PA 14 062 Funding Number: PA 14 062 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PA 14 063 Funding Number: PA 14 063 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (U01) Apply for PAR 14 067 Funding Number: PAR 14 067 Agency: National Institutes of Health Category: Education Health Funding Amount: $700,000 |
| Centers of Excellence in Self Management Building Research Teams for the Future (P20) Apply for RFA NR 14 001 Funding Number: RFA NR 14 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 14 025", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.